Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_assertion type Assertion NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_head.
- NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_assertion description "[Finally, gemcitabine treatment of control animals and p48-Cre/LSL-Kras(G12D) animals with pancreatic cancer caused distinct and up to 60-fold changes in circulating miRs that indicate differential drug effects on normal and cancer tissues.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_provenance.
- NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_assertion evidence source_evidence_literature NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_provenance.
- NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_assertion SIO_000772 21738581 NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_provenance.
- NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_assertion wasDerivedFrom befree-20140225 NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_provenance.
- NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_assertion wasGeneratedBy ECO_0000203 NP909105.RAZs0pLm_j9Sja99lTL_iu1c7fArRrJMpPffbHg2_djlA130_provenance.